FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375947498> ?p ?o ?g. }

• W4375947498 endingPage "1139" @default.
• W4375947498 startingPage "1127" @default.
• W4375947498 abstract "ABSTRACT. For a malaria elimination strategy, Haiti’s National Malaria Control Program piloted a mass drug administration (MDA) with indoor residual spraying (IRS) in 12 high-transmission areas across five communes after implementing community case management and strengthened surveillance. The MDA distributed sulfadoxine–pyrimethamine and single low-dose primaquine to eligible residents during house visits. The IRS campaign applied pirimiphos–methyl insecticide on walls of eligible houses. Pre- and post-campaign cross-sectional surveys were conducted to assess acceptability, feasibility, drug safety, and effectiveness of the combined interventions. Stated acceptability for MDA before the campaign was 99.2%; MDA coverage estimated at 10 weeks post-campaign was 89.6%. Similarly, stated acceptability of IRS at baseline was 99.9%; however, household IRS coverage was 48.9% because of the high number of ineligible houses. Effectiveness measured by Plasmodium falciparum prevalence at baseline and 10 weeks post-campaign were similar: 1.31% versus 1.43%, respectively. Prevalence of serological markers were similar at 10 weeks post-campaign compared with baseline, and increased at 6 months. No severe adverse events associated with the MDA were identified in the pilot; there were severe adverse events in a separate, subsequent campaign. Both MDA and IRS are acceptable and feasible interventions in Haiti. Although a significant impact of a single round of MDA/IRS on malaria transmission was not found using a standard pre- and post-intervention comparison, it is possible there was blunting of the peak transmission. Seasonal malaria transmission patterns, suboptimal IRS coverage, and low baseline parasitemia may have limited the effectiveness or the ability to measure effectiveness." @default.
• W4375947498 created "2023-05-10" @default.
• W4375947498 creator A5011752709 @default.
• W4375947498 creator A5012365729 @default.
• W4375947498 creator A5013958215 @default.
• W4375947498 creator A5018561836 @default.
• W4375947498 creator A5022773355 @default.
• W4375947498 creator A5029164007 @default.
• W4375947498 creator A5032341392 @default.
• W4375947498 creator A5033821720 @default.
• W4375947498 creator A5037076197 @default.
• W4375947498 creator A5044797461 @default.
• W4375947498 creator A5049761946 @default.
• W4375947498 creator A5053479822 @default.
• W4375947498 creator A5057726286 @default.
• W4375947498 creator A5057849978 @default.
• W4375947498 creator A5058620441 @default.
• W4375947498 creator A5061299226 @default.
• W4375947498 creator A5062320027 @default.
• W4375947498 creator A5063894840 @default.
• W4375947498 creator A5064557027 @default.
• W4375947498 creator A5064736600 @default.
• W4375947498 creator A5067737398 @default.
• W4375947498 creator A5070879893 @default.
• W4375947498 creator A5080428849 @default.
• W4375947498 creator A5082255981 @default.
• W4375947498 creator A5090005964 @default.
• W4375947498 creator A5092343411 @default.
• W4375947498 creator A5092343412 @default.
• W4375947498 date "2023-06-07" @default.
• W4375947498 modified "2023-10-17" @default.
• W4375947498 title "Acceptability, Feasibility, Drug Safety, and Effectiveness of a Pilot Mass Drug Administration with a Single Round of Sulfadoxine–Pyrimethamine Plus Primaquine and Indoor Residual Spraying in Communities with Malaria Transmission in Haiti, 2018" @default.
• W4375947498 cites W1549510969 @default.
• W4375947498 cites W1918104211 @default.
• W4375947498 cites W2045936441 @default.
• W4375947498 cites W2275939958 @default.
• W4375947498 cites W2294334755 @default.
• W4375947498 cites W2302939988 @default.
• W4375947498 cites W2485300145 @default.
• W4375947498 cites W2560080836 @default.
• W4375947498 cites W2617508148 @default.
• W4375947498 cites W2625589185 @default.
• W4375947498 cites W2766596232 @default.
• W4375947498 cites W2806462273 @default.
• W4375947498 cites W2808720208 @default.
• W4375947498 cites W2809236965 @default.
• W4375947498 cites W2889248076 @default.
• W4375947498 cites W2890595791 @default.
• W4375947498 cites W2899285266 @default.
• W4375947498 cites W2909719891 @default.
• W4375947498 cites W2954138883 @default.
• W4375947498 cites W2965022894 @default.
• W4375947498 cites W2993325277 @default.
• W4375947498 cites W3001160117 @default.
• W4375947498 cites W3014681265 @default.
• W4375947498 cites W3024714861 @default.
• W4375947498 cites W3032789551 @default.
• W4375947498 cites W3160557198 @default.
• W4375947498 cites W3164541055 @default.
• W4375947498 cites W3167889309 @default.
• W4375947498 cites W4210316523 @default.
• W4375947498 cites W4211253880 @default.
• W4375947498 cites W4213342046 @default.
• W4375947498 cites W4226207949 @default.
• W4375947498 cites W4290664479 @default.
• W4375947498 cites W4367596251 @default.
• W4375947498 doi "https://doi.org/10.4269/ajtmh.22-0623" @default.
• W4375947498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37160282" @default.
• W4375947498 hasPublicationYear "2023" @default.
• W4375947498 type Work @default.
• W4375947498 citedByCount "1" @default.
• W4375947498 crossrefType "journal-article" @default.
• W4375947498 hasAuthorship W4375947498A5011752709 @default.
• W4375947498 hasAuthorship W4375947498A5012365729 @default.
• W4375947498 hasAuthorship W4375947498A5013958215 @default.
• W4375947498 hasAuthorship W4375947498A5018561836 @default.
• W4375947498 hasAuthorship W4375947498A5022773355 @default.
• W4375947498 hasAuthorship W4375947498A5029164007 @default.
• W4375947498 hasAuthorship W4375947498A5032341392 @default.
• W4375947498 hasAuthorship W4375947498A5033821720 @default.
• W4375947498 hasAuthorship W4375947498A5037076197 @default.
• W4375947498 hasAuthorship W4375947498A5044797461 @default.
• W4375947498 hasAuthorship W4375947498A5049761946 @default.
• W4375947498 hasAuthorship W4375947498A5053479822 @default.
• W4375947498 hasAuthorship W4375947498A5057726286 @default.
• W4375947498 hasAuthorship W4375947498A5057849978 @default.
• W4375947498 hasAuthorship W4375947498A5058620441 @default.
• W4375947498 hasAuthorship W4375947498A5061299226 @default.
• W4375947498 hasAuthorship W4375947498A5062320027 @default.
• W4375947498 hasAuthorship W4375947498A5063894840 @default.
• W4375947498 hasAuthorship W4375947498A5064557027 @default.
• W4375947498 hasAuthorship W4375947498A5064736600 @default.
• W4375947498 hasAuthorship W4375947498A5067737398 @default.
• W4375947498 hasAuthorship W4375947498A5070879893 @default.
• W4375947498 hasAuthorship W4375947498A5080428849 @default.
• W4375947498 hasAuthorship W4375947498A5082255981 @default.
• W4375947498 hasAuthorship W4375947498A5090005964 @default.
• W4375947498 hasAuthorship W4375947498A5092343411 @default.

• next